Good afternoon, We that thank doing you everyone, for hope joining well. us. and you're Lynn. Thanks,
year. XXXX. XXXX afternoon's quarter this first represents As second you the this are sequential with strong continuing XX% of the from the release, saw in growth XX% to of the $XX in This press second growth total of the quarter quarter we million momentum compared over quarter first and over revenue for
against among in U.S., each many quarter rise. growth our a with primarily physicians growth patient due some all complemented desire we stabilizing we solid volumes platforms rebounding performance of major these treatments to and critical that in top-line and have in the backlog. a markets Europe new of To procedure in patient across accelerating throughout continues patients The of to driven the increasing Asia. robust to was of to flow, recovery activity access portion facilities. end, with the backdrop experienced existing penetration strong franchises saw by sites Our More encouragingly, by small in and
As strong. energy quarter, across July we third remains our business, started and begin the positive
seen we areas we COVID we see continue is some procedures While expect back the while started in have – slowdown half year. to where to have a strong in of surging,
start will clinical an we trial. on with aMAZE Now the update
acquisition patient April. As to we a enrollment in of then reminder, More after past in clinical the modular trial late trial began follow-up we XXXX this the recently, were the final data. completed finished and shortly PMA aMAZE submissions unblinded August SentreHEART, XXXX the
are achieving we the the of of goal, the met. While the aMAZE sharing not efficacy despite summary, today, results primary in endpoint safety was primary details trial not
and our trial evaluate are data as learning the Medical We more we Board in still with and Advisory the FDA. discussions engage
the However, time. this at pathway uncertain for is PMA submission
going for core Although investment and we leverage forward. value we hope the a by there space, an robust a unique community, have different of of believe with the in aMAZE includes in we is built underpinning from outcome will continue safety that results are This trial, portfolio the that since and an experienced the IP an and SentreHEART encouraged to and from lab EP relationships team complements knowledge setting clinical EP technical with our we technologies.
our population will Afib and supported products, we for expanding growing unchanged. innovation by for businesses all Therefore, continue science portfolio conviction vast our forward, move of treatment the building of of a differentiated remains clinical patients. options across we As
Let's our now initiatives. turn – turn in to now key growth the let's many advancements
using superiority more treatment of of and these long-standing approval advanced CONVERGE the device long-standing the half only most FDA AF of system AtriCure resulted million form for to approval PMA with with represent which alone. for persistent in catheter to Patients Afib. therapy persistent of EPi-Sense demonstrated treatment than trial, receive disease, ablation from for by The market. The second providing endocardial EPi-Sense first difficult-to-treat the quarter was with the groundbreaking stand-alone the sustainable nearly of the This patients hybrid transformative Afib, and patients patients, critical XX of system the worldwide. and affected EPi-Sense the the is Afib approval differentiation
train benefits clear of provides the EPi-Sense physicians hybrid Our a marks AF to of improve lives us company. of therapy patients. educate to approval this on millions and our achievement system The underserved opportunity help the in the pivotal ability moment with is and the
of executing now sites is both hybrid and communities. and engaging first team FDA we Leading our In following close results AF from hosted faculty-guided training cardiology and was to new between launch, where awareness event, late hybrid April. sales June, many within U.S. the questions. discussions throughout on on dialogue addressed the rich peer-to-peer that clinical collaboration and specialties. EP our existing therapy expert emphasizing therapy approval one patient commercial a Our driving AF This quarter and inaugural activities late event benefit training in just the
for hybrid standard for of to persistent utilizing millions care long-standing is therapy the the the goal AF of patients Afib. become Our device the with EPi-Sense
the next simpler over appeal provides a open device XXX(k)clearance open surgery open we leader the procedures we deepening EnCompass addition in of Afib. innovative the surgery our And we The This penetration ablation decade. EnCompass for expect ablating high-volume an cardiac the broad the announce our heart and platform, have device procedures. to Clamp approach surgeons, in will our to faster market to are the to cardiac a where in we've the are Moving market for pleased franchise, treatment is that to Clamp. got cardiac
small It to the decade persistent begun to centers persistent of synergy full at isolator and have commercial year. later a limited AtriCure's approved number FDA a We launch concomitant that the this long-standing surgical ago expect system nearly move by of was for a launch and Afib. treatment was
FDA for treatment the persistent therapy, our for of invasive minimally hybrid advantage AF the devices system AtriCure of approval has world for two EPi-Sense long-standing a only approval clear Afib, ablation recent the and platforms. the With with open providing in
reiterate quarter. here addressable a representing is patients from platforms franchise first message is market opportunity The ablation thousands And alone by further our opportunity pause to So meaningful, let the our sequential boosted left well hundreds in annually. for dollars, XX% management while ablation of quarter. first Worldwide, of our billions it appendage management is collective procedures. of the steady and the into over atrial growth atrial rise appendage left the me delivered
surgical first reduces LAA was atrial XX that for different after at undergoing New atrial AtriClip management published in XX% of cardiac be demonstrate days. of by systemic with the recent This as Surgical countries. body stroke Annual appendage was late-breaker surgery approaches a of England the Medicine stroke LAA and in study by perioperative to We XX increasing randomized of and appendage College the Cardiology excited significantly clinical patients to occlusion Journal ischemic or found patients the occlusion that Afib study and at overall centers embolism. of management by and the XX% first the American for including growing a left Over X,XXX Meeting. ischemic controlled study XXX independent left need the in management surgical continue awareness reduce to were May part presented evidence, was
identified the safety issues study. Importantly, there were in significant no
postoperative left the proposal the reimbursement appendage Additionally, atrial codes. a management with for CPT CMS XXXX. when in positive proposed And finally, key groundswell current positions, or this the procedural news AtriClip rates surgical the by in take pain on societies We the effect we for change for our patients. franchise and of managing support for new believe from the creating cryoSPHERE thoracic reflects probe, another welcome device terminology, tailwind touching dedicated
represents is worldwide one this X% and franchise pain after form a of of nerves of patients. in cardiothoracic surgery, changing from differentiated which to is relief Cryo facilities therapies are transmitting included our revenue to technology Nerve unique approach their pain care now signals of Nearly long-lasting providing method Our unique pain our incorporate uses XXX to in Block, year-to-date. the management. fastest-growing for block freezing a standard U.S. revenue approximately open
We we are still the for the ongoing Cryo the accounts the widely new remains therapy this Block customers. Nerve traction existing Yes, seeing we believe are expansion to underpenetrated. market is but progress, pleased with in and great
result, closing, we In increase and our commercial to teams ahead. dedicated in and broadening continuing by truly awareness are education a our excited adoption. investments therapy are our we as bright As we future and drive portfolio
of While Officer, we a business detailed beyond. the XXXX continue our to Angie of I Wirick, to on many and our over call the confident results Financial growth more now recovery, team, underlying remain our of the in we in catalysts Chief turn accelerate strength resiliency quarter. to the and will discuss pathway our toward
